Inventor · disambiguated record
Charles A. Gersbach
Also filed as: GERSBACH CHARLES · GERSBACH CHARLES A
20 granted patents·36 pending applications·187 citations·filing 2013–2024
95Inventor score
Top patents by PatentIndex Score
56 records- 0196US11976307B2Genetic correction of mutated genesUNIV DUKE·Filed 2020·Granted May 7, 2024·4 cites·15 claims
- 0296US11155796B2Compositions and methods for epigenome editingUNIV DUKE·Filed 2020·Granted Oct 26, 2021·10 cites·13 claims
- 0394US11421251B2Genome engineering with type I CRISPR systems in eukaryotic cellsUNIV DUKE·Filed 2020·Granted Aug 23, 2022·11 cites·16 claims
- 0494US10745714B2RNA-guided gene editing and gene regulationUNIV DUKE·Filed 2018·Granted Aug 18, 2020·21 cites·17 claims
- 0594US10711256B2Genetic correction of mutated genesUNIV DUKE·Filed 2017·Granted Jul 14, 2020·10 cites·16 claims
- 0694US10704060B2RNA-guided gene editing and gene regulationUNIV DUKE·Filed 2014·Granted Jul 7, 2020·51 cites·10 claims
- 0794US10676726B2Compositions and methods for epigenome editingUNIV DUKE·Filed 2016·Granted Jun 9, 2020·13 cites·4 claims
- 0893US12428631B2CRISPR/Cas9-based repressors for silencing gene targets in vivo and methods of useUNIV DUKE·Filed 2024·Granted Sep 30, 2025·1 cites·19 claims
- 0993US9738879B2Genetic correction of mutated genesUNIV DUKE·Filed 2013·Granted Aug 22, 2017·20 cites·6 claims
- 1091US12215366B2Compositions and methods for epigenome editingUNIV DUKE·Filed 2021·Granted Feb 4, 2025·1 cites·12 claims
- 1190US9828582B2Compositions and methods for the induction and tuning of gene expressionUNIV DUKE·Filed 2014·Granted Nov 28, 2017·9 cites·1 claims
- 1287US2025257341A1Compositions and methods for epigenome editingUNIV DUKE·Filed 2024·Application pending·0 cites
- 1386US11970710B2Genome engineering with Type I CRISPR systems in eukaryotic cellsUNIV DUKE·Filed 2016·Granted Apr 30, 2024·4 cites·17 claims
- 1486US11427817B2Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleasesUNIV DUKE·Filed 2016·Granted Aug 30, 2022·11 cites·11 claims
- 1585US11319555B2Compositions, systems and methods for cell therapyUNIV DUKE·Filed 2015·Granted May 3, 2022·3 cites·4 claims
- 1685US10676735B2High-throughput screening of regulatory element function with epigenome editing technologiesUNIV DUKE·Filed 2016·Granted Jun 9, 2020·13 cites·17 claims
- 1781US2024336892A1Compositions and methods for the induction and tuning of gene expressionUNIV DUKE·Filed 2024·Application pending·0 cites
- 1880US12215345B2Compositions and methods for the induction and tuning of gene expressionUNIV DUKE·Filed 2017·Granted Feb 4, 2025·1 cites·8 claims
- 1975US12214056B2Therapeutic applications of CPF1-based genome editingUNIV DUKE·Filed 2017·Granted Feb 4, 2025·1 cites·12 claims
- 2073US12214054B2Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of useUNIV DUKE·Filed 2016·Granted Feb 4, 2025·2 cites·16 claims
- 2170US2025114482A1Therapeutic applications of cpf1-based genome editingUNIV DUKE·Filed 2024·Application pending·0 cites
- 2268US2023304000A1Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleasesUNIV DUKE·Filed 2022·Application pending·0 cites
- 2367US2025197823A1Compositions and methods for epigenome editing to enhance t cell therapyUNIV DUKE·Filed 2023·Application pending·0 cites
- 2467US2023047669A1Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleasesUNIV DUKE·Filed 2022·Application pending·0 cites
- 2565US2025171754A1Crispr-cas9 compositions and methods with a novel cas9 protein for genome editing and gene regulationUNIV DUKE·Filed 2023·Application pending·0 cites
- 2664US2021002665A1Rna-guided gene editing and gene regulationUNIV DUKE·Filed 2020·Application pending·0 cites
- 2764US2025262326A1Effector domains for crispr-cas systemsUNIV DUKE·Filed 2023·Application pending·0 cites
- 2863US2022315946A1Compositions, systems and methods for cell therapyUNIV DUKE·Filed 2022·Application pending·0 cites
- 2961US2024254483A1Compositions and methods for modulating expression of frataxin (fxn)TUNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3061US2023392132A1Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophyUNIV DUKE·Filed 2021·Application pending·0 cites
- 3160US10954513B2RNA-guided transcriptional regulation and methods of using the same for the treatment of back painBOWLES ROBERT D·Filed 2016·Granted Mar 23, 2021·1 cites·18 claims
- 3260US2023383297A1Novel targets for reactivation of prader-willi syndrome-associated genesUNIV DUKE·Filed 2021·Application pending·0 cites
- 3359US2024026352A1Targeted gene regulation of human immune cells with crispr-cas systemsUNIV DUKE·Filed 2021·Application pending·0 cites
- 3457US2024252684A1Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)TUNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3557US2023348870A1Gene editing of satellite cells in vivo using aav vectors encoding muscle-specific promotersUNIV DUKE·Filed 2021·Application pending·0 cites
- 3656US2023257723A1Crispr/cas9 therapies for correcting duchenne muscular dystrophy by targeted genomic integrationUNIV DUKE·Filed 2021·Application pending·0 cites
- 3756US2023383270A1Crispr/cas-based base editing composition for restoring dystrophin functionUNIV DUKE·Filed 2021·Application pending·0 cites
- 3856US2022364124A1Epigenetic modulation of genomic targets to control expression of pws-associated genesUNIV DUKE·Filed 2020·Application pending·0 cites
- 3956US2023201375A1Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)UNIV DUKE·Filed 2021·Application pending·0 cites
- 4056US2023159927A1Chromatin remodelers to enhance targeted gene activationUNIV DUKE·Filed 2021·Application pending·0 cites
- 4155US2022305141A1Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activatorsUNIV DUKE·Filed 2020·Application pending·0 cites
- 4255US2019127713A1Crispr/cas9-based repressors for silencing gene targets in vivo and methods of useUNIV DUKE·Filed 2017·Application pending·0 cites
- 4354US2025134999A1Compositions, systems, and methods for programming t cell phenotypes through targeted gene activationTUNE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4454US2024058425A1Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitnessUNIV DUKE·Filed 2023·Application pending·0 cites
- 4554US2025154503A1Compositions, systems, and methods for programming t cell phenotypes through targeted gene repressionTUNE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4653US2023349888A1A high-throughput screening method to discover optimal grna pairs for crispr-mediated exon deletionUNIV DUKE·Filed 2021·Application pending·0 cites
- 4752US2023032846A1Systems and methods for lipid nanoparticle delivery of gene editing machineryUNIV DUKE·Filed 2020·Application pending·0 cites
- 4852US2024141341A1Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitnessUNIV DUKE·Filed 2022·Application pending·0 cites
- 4952US2022195406A1Crispr/cas-based genome editing composition for restoring dystrophin functionUNIV DUKE·Filed 2020·Application pending·0 cites
- 5051US2022307015A1Compositions and methods for identifying regulators of cell type fate specificationUNIV DUKE·Filed 2020·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Charles A. Gersbach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →